Evidence map›Paper›PMID 21448777›Full record

ArticleMolecular imaging and biology2012

Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.

Olli Eskola, Tove J Grönroos, Sarita Forsback, Johanna Tuomela, Gaber Komar, Jörgen Bergman, Pirkko Härkönen, Merja Haaparanta, Heikki Minn, Olof Solin

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Repeatability of tumour hypoxia imaging using [European journal of nuclear medicine and molecular imaging · 2018
    Trial
  2. Closing the gap betweenEJNMMI radiopharmacy and chemistry · 2021
    Review
  3. The feasibility of [EJNMMI research · 2020
    Article
  4. Article
  5. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014
    Article
  6. Uptake of [Translational oncology · 2014
    Article
  7. Article
  8. Imaging hypoxia to improve radiotherapy outcome.Nature reviews. Clinical oncology · 2012
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Olli EskolaTurku PET Centre, Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland. olesko@utu.fi
Tove J Grönroos
Sarita Forsback
Johanna Tuomela
Gaber Komar
Jörgen Bergman
Pirkko Härkönen
Merja Haaparanta
Heikki Minn
Olof Solin
University of Turku · FIÅbo Akademi University · FIPharmatest (Finland) · FITurku PET Centre · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide labeled with [(18)F]-fluorine ([(18)F]EF5), a promising tracer for tumor hypoxia, has previously been synthesized in low yields and low specific radioactivity. In pharmacokinetic evaluations, in the presence of non-radioactive EF5, a uniform and low background uptake and high in vivo stability of [(18)F]EF5 have been demonstrated. Our purpose was to increase the specific radioactivity of [(18)F]EF5 to enable to study the pharmacokinetics at trace level. PROCEDURES: [(18)F]EF5 was synthesized using high specific radioactivity electrophilic [(18)F]F(2) as labelling reagent. Biodistribution of [(18)F]EF5 was determined in a prostate tumor mouse model, and formation of radiolabelled metabolites was studied in mouse, rat and human plasma.

resultsOn average, 595 ± 153 MBq of [(18)F]EF5 was produced. Specific radioactivity was 6.6 ± 1.9 GBq/μmol and the radiochemical purity exceeded 99.0%. [(18)F]EF5 was distributed uniformly in tissues, with highest uptake in liver, kidney, and intestine. Several radiolabelled metabolites were detected in mouse plasma and tissues, whereas low amounts of metabolites were detected in human and rat plasma.

conclusions[(18)F]EF5 was synthesized by electrophilic labelling with high quality and high yields. Pharmacokinetics of [(18)F]EF5 was determined at trace level in several species. Our results suggest that the trace-level approach does not affect the biodistribution of [(18)F]EF5. Extensive metabolism was seen in mouse.

Indexed as

AnimalsCell HypoxiaCell Line, TumorChromatography, High Pressure LiquidChromatography, Thin LayerEtanidazoleFluorine RadioisotopesFluorocarbonsHumansHydrocarbons, FluorinatedIsomerismMaleMiceRadioactive TracersRatsTissue Distribution2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamideEtanidazoleFluorine RadioisotopesFluorocarbonsHydrocarbons, FluorinatedRadioactive Tracers

Identifiers

PMID21448777
OpenAlexW2029022566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.